Gan&Lee Pharmaceuticals's Insulin New Factory Completed in Brazil

Consumer Staples Author: Notrice May 15, 2024 04:53 PM (GMT+8)

EqualOcean has learned that Gan&Lee Pharmaceuticals(甘李药业) has made significant progress in its insulin production cooperation with the Brazilian local enterprise Biomm S.A. (hereinafter referred to as Biomm), signaling the official completion of the insulin new factory in Brazil. This signifies a significant achievement in Gan&Lee Pharmaceuticals's strategic deployment in overseas markets, including Brazil.


During the inauguration ceremony, Gan&Lee Pharmaceuticals's CEO, Du Kai(都凯), led the business team to the site, witnessing this historic moment together with Brazilian President Lula, Biomm's CEO Heraldo, and others. Nearly twenty mainstream Brazilian media outlets have focused on reporting the significant progress of Gan&Lee Pharmaceuticals in the Brazilian market. At the ceremony, CEO Du Kai presented a 10th-anniversary gift to Biomm CEO Heraldo, celebrating the deepening and mutually beneficial cooperation between the two parties. This celebration holds extraordinary significance for the cooperation between the two parties and also enhances Gan&Lee Pharmaceuticals's international brand influence.

Founded in 1998, Gan&Lee Pharmaceuticals is a high-tech biopharmaceutical company integrating research, development, production, and sales, with over 4,000 employees worldwide. Headquartered in the southern area of Beijing Tongzhou Economic Development Zone, it belongs to the Zhongguancun National Independent Innovation Demonstration Zone, with an industrial park covering approximately 200,000 square meters.

According to EqualOcean, Brazil has the highest number of diabetes patients in Latin America, creating a huge demand for insulin. The completion of the new factory will greatly improve the accessibility and affordability of insulin in Brazil, bringing positive social and economic benefits to local patients and the healthcare payment system.

Previously, Gan&Lee Pharmaceuticals and the Brazilian local enterprise Biomm began in-depth cooperation as early as 2014, and completed the first batch of commercial shipments to Biomm in 2020. Through technology transfer cooperation with Ganli, Biomm has successfully achieved localized production of products this year, becoming the first local enterprise in Brazil with insulin production capabilities. Currently, Biomm's insulin production base in Minas Gerais state has obtained approval from the Brazilian health regulatory agency ANVISA and can officially commence production.

Currently, Gan&Lee Pharmaceuticals's various insulin products have been successively approved for listing in Brazil, including Ganli insulin injection, prefilled pens, and insulin repeating pens. The successful listing of these products not only fully demonstrates the company's strength but also further consolidates its position in the Brazilian market.

The completion of the new factory not only injects new impetus into Gan&Lee Pharmaceuticals's development in the Brazilian market but also provides strong support for the company's future internationalization strategy. Gan&Lee Pharmaceuticals stated that it will continuously promote the development of the Brazilian pharmaceutical industry by exporting advanced insulin production technology, providing professional technical support, and diversifying cooperation methods, in order to provide higher quality products and services to more patients.

As a company dedicated to the research and production of high-quality drugs, Gan&Lee Pharmaceuticals has always emphasized product quality and innovation. With unique pharmaceutical technology and strict quality control, Gan&Lee Pharmaceuticals has gained widespread recognition in the Brazilian market. As a representative insulin manufacturer in China, Gan&Lee Pharmaceuticals has been committed to providing high-quality products and services to diabetes patients worldwide. With further expansion into the international market and gradual improvement of overseas layout, Gan&Lee Pharmaceuticals is expected to achieve greater commercial value and technological breakthroughs. At the same time, this will also establish a more positive brand image and position for Chinese pharmaceutical companies in the global market.